PL366398A1 - Method of preventing type 2 diabetes with aerosolized insulin - Google Patents

Method of preventing type 2 diabetes with aerosolized insulin

Info

Publication number
PL366398A1
PL366398A1 PL02366398A PL36639802A PL366398A1 PL 366398 A1 PL366398 A1 PL 366398A1 PL 02366398 A PL02366398 A PL 02366398A PL 36639802 A PL36639802 A PL 36639802A PL 366398 A1 PL366398 A1 PL 366398A1
Authority
PL
Poland
Prior art keywords
diabetes
preventing type
aerosolized insulin
aerosolized
insulin
Prior art date
Application number
PL02366398A
Other languages
English (en)
Polish (pl)
Inventor
Alan Seth Krasner
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL366398A1 publication Critical patent/PL366398A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL02366398A 2001-05-04 2002-04-08 Method of preventing type 2 diabetes with aerosolized insulin PL366398A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28873201P 2001-05-04 2001-05-04
PCT/IB2002/001216 WO2002089916A1 (en) 2001-05-04 2002-04-08 Method of preventing type 2 diabetes with aerosolized insulin

Publications (1)

Publication Number Publication Date
PL366398A1 true PL366398A1 (en) 2005-01-24

Family

ID=23108398

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02366398A PL366398A1 (en) 2001-05-04 2002-04-08 Method of preventing type 2 diabetes with aerosolized insulin

Country Status (11)

Country Link
US (1) US20020164267A1 (cg-RX-API-DMAC10.html)
EP (1) EP1387713A1 (cg-RX-API-DMAC10.html)
JP (1) JP2004533438A (cg-RX-API-DMAC10.html)
KR (1) KR20030094377A (cg-RX-API-DMAC10.html)
CN (1) CN1507362A (cg-RX-API-DMAC10.html)
CA (1) CA2445944A1 (cg-RX-API-DMAC10.html)
HU (1) HUP0400083A2 (cg-RX-API-DMAC10.html)
IL (1) IL158192A0 (cg-RX-API-DMAC10.html)
PL (1) PL366398A1 (cg-RX-API-DMAC10.html)
WO (1) WO2002089916A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200307564B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054606A1 (en) * 2002-12-13 2004-07-01 Pfizer Products Inc. Method of decreasing hepatic glucose output in diabetic patients
WO2007098392A2 (en) * 2006-02-21 2007-08-30 Glaxo Group Limited Method and system for chemical specific spectral analysis
EP2060268A1 (en) * 2007-11-15 2009-05-20 Novo Nordisk A/S Pharmaceutical compositions for pulmonary or nasal delivery of peptides
US20190343768A1 (en) * 2018-05-14 2019-11-14 Dance Biopharm Inc. Insulin formulations for reconstitution into high concentration liquid solutions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5915378A (en) * 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5873358A (en) * 1993-01-29 1999-02-23 Aradigm Corporation Method of maintaining a diabetic patient's blood glucose level in a desired range
US5743250A (en) * 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5970973A (en) * 1993-01-29 1999-10-26 Aradigm Corporation Method of delivering insulin lispro
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5891288A (en) * 1997-09-23 1999-04-06 Proulx Manufacturing, Inc. Process for forming double-strand edged monofilament line for use in line trimmers
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
AU5613999A (en) * 1998-09-18 2000-04-10 University Of British Columbia, The Pharmaceutical compositions of vanadium biguanide complexes and their use
US6187291B1 (en) * 1998-09-28 2001-02-13 Robert Weinstein Method and device for facilitating combined aerosol and oral treatments for diabetes mellitus
HRP20010795A2 (en) * 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
US6447750B1 (en) * 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US20020147134A1 (en) * 2001-04-06 2002-10-10 Geho W. Blair Method of preventing and treating the complications of insulin dependent diabetes mellitus
US6447751B1 (en) * 2001-04-18 2002-09-10 Robert E. Weinstein Method and device for facilitating combined aerosol and oral treatments for diabetes mellitus
MXPA03000966A (es) * 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.

Also Published As

Publication number Publication date
JP2004533438A (ja) 2004-11-04
EP1387713A1 (en) 2004-02-11
CA2445944A1 (en) 2002-11-14
CN1507362A (zh) 2004-06-23
IL158192A0 (en) 2004-03-28
ZA200307564B (en) 2004-09-29
US20020164267A1 (en) 2002-11-07
KR20030094377A (ko) 2003-12-11
HUP0400083A2 (hu) 2004-04-28
WO2002089916A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
HRP20030949A2 (en) Pulmonary administration of chemically modified insulin
ZA200402688B (en) Method and composition for preventing or reducing the symptons of insulin resistance syndrome.
AU2002248464A1 (en) Stabilized insulin formulations
AU3600699A (en) Method for regulating insulin medication
AU3068599A (en) Medication infusion set
IL137105A0 (en) Method for administering aspb28-human insulin
AU2002359919A1 (en) Syringe
AU2000276362A1 (en) Composition for the treatment of diabetes
AU2003251933A8 (en) Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
AU2002323484A1 (en) Insulin related transcription factor and uses thereof
AU4671000A (en) Method of enhancing insulin action
AU2002309083A1 (en) Method for identifying drugs for the treatment of type ii diabetes
IL161073A0 (en) Composition and method for treating diabetes
IL158192A0 (en) Method of preventing type 2 diabetes with aerosolized insulin
AU2002327440A1 (en) Treatment of type i diabetes
AU2002240004A1 (en) Infusion cannula
AU2003231279A1 (en) Prevention and treatment of type 2 diabetes
AU2002255704A1 (en) Novel anti-adhesive compounds and uses thereof
IL161388A0 (en) Method of reducing type 2 diabetes in high risk patients
AU2001268474A1 (en) Use of amp kinase activators for treatment of type 2 diabetes and insulin resistance
AU2002349142A1 (en) Syringe
HUP0303523A3 (en) Modified insulin with reduced immunogenicity
AU2002344611A1 (en) Method of diagnosing type 2 diabetes
AU2001100420A4 (en) Bedside needlestick prevention unit
AU2001262786A1 (en) Use of l-2-oxothiazolidine-4-carboxylic acid for the treatment of type 2 diabetes

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)